IVD

mariPOC®

Point-of-Care Testing for Respiratory Diagnostics

Virology

Innovation with Integrity

mariPOC® - A fully automated continuous-feed immunoassay analyzer

The mariPOC® System is a compact solution for high-throughput, rapid Point-Of-Care (POC) testing needs that analyses swab samples fully automated. With a workflow of less than 3 minutes hands-on time and no need for additional instrumentation, it is an easy-to-use tool to test for pathogens anywhere by suitably trained individuals and in accordance with local regulations. It utilizes modern two-photon excitation fluorometry in combination with immunoassay-based testing to achieve a specificity and sensitivity so far only achieved by state-of-the-art immunoassay laboratories.

Access to SARS-CoV-2 testing everywhere

The mariPOC® SARS-CoV-2 test supports detection of acute and contagious COVID-19 disease at the site of sampling. An indicative positive result from nasopharyngeal samples can be obtained after 20 minutes for highly positive infections, a final confirmative positive or negative result can be read after 90 minutes. Minimal work steps, automated analysis and the easy-to-use interface allow the use even with a large number of patients of up to 300 samples per 24 hours.

Prepared for POC testing in winter

The mariPOC® Respi+ test allows point-of-care testing for a broad panel of respiratory-related pathogens covering SARS-CoV-2, Influenza, RSV, Adenovirus, Metapneumovirus, Parainfluenza, Coronavirus OC43 and *Streptococcus pneumoniae*. From just one sample you get automated analysis for all these pathogens from nasopharyngeal swabs. The indicative positive result is available after 20 minutes for highly positive infections and a final confirmative result to identify if any of the pathogens is positive can be read after 2 hours.

Performance and result interpretation

mariPOC® SARS-CoV-2

Pathogen	Sensitivity (N)	Specificity (N)
SARS coronavirus 2	92.3% (12/13)[1]	100% (198/198)[1]

[1] Compared to PCR



mariPOC® Respi+

Pathogen	Sensitivity (N)	Specificity (N)
SARS coronavirus 2	92.3% (12/13)[1]	100% (198/198)[1]
Influenza A virus	92.3% (24/26)[1]	99.8% (870/872)[1]
Influenza B virus	87.5% (35/40)[1]	100% (152/152)[1]
Respiratory Syncytial Virus	88.6% (31/35)[1]	100% (123/123)[1]
Human metapneumovirus	77.8% (7/9)[1]	100% (195/195)[1]
Humona coronavirus OC43	NA	100% (159/160)[1]
S. pneumoniae	Similar[2]	No cross-reactions
Parainfluenza 1 virus	Similar[3]*	99% (198/200)[1]
Parainfluenza 2 virus	Similar[3]*	99% (198/200)[1]
Parainfluenza 3 virus	Similar[3]*	99% (200/202)[1]
Adenovirus	92.3% (24/26)[3]	100% (202/202)[1]

[1] Compared to PCR
[2] Compared to rapid antigen test
[3] Compared to time-resolved fluoroimmunoassay (TR-FIA)
* Defined by antigen dilution series with TR-FIA due to low incidence of positive clinical samples



Order Information:

Part No. 1204S | mariPOC® SARS-CoV-2
Tests/plate: 308
Sample capacity: 308 samples/24 h

Part No. 1184M | mariPOC® Respi+
Tests/plate: 22
Sample capacity: 100 samples/24 h

Part No. H-AD7-020 | mariPOC® AD7-020 analyzer
System for use with mariPOC® tests

For more information, please get in touch with one of our local offices:

Hain Lifescience GmbH - a Bruker company
Phone: +49 (0) 7473 9451 0
info.mdx.de@bruker.com

Biocentric - a Bruker company
Phone: +33 (0) 4 94 29 06 30
info.mdx.fr@bruker.com

Hain Lifescience Spain SL - a Bruker company
Phone: +34 (0) 886 12 42 51
info.mdx.es@bruker.com

Bruker UK Ltd.
Phone: +44 (0) 7920 245 666
info.mdx.uk@bruker.com

CE IVD

ArcDia International Oy Ltd.
Turku · Finland
Phone +358 40 6787 414

Bruker Daltonik GmbH
Bremen · Germany
Phone +49 (0) 421-2205-0

ms.sales.bdal@bruker.com - www.bruker.com/microbiology